They carried out a feasibility study using the 18F-canagliflozin PET imaging to assess the association between clinical canagliflozin doses and SGLT2 occupancy in patients with type 2 diabetes, providing valuable insights into drug distribution in vivo [69]. Here, SLC5A2 is linked to type 2 diabetes mellitus.